Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19219183 | DESMOPRESSIN ORAL COMPOSITIONS | May 2025 | November 2025 | Allow | 6 | 1 | 0 | No | No |
| 18955504 | DESMOPRESSIN ORAL COMPOSITIONS | November 2024 | May 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18926573 | Methods and Compositions for Delivery of Biotin to Mitochondria | October 2024 | October 2025 | Allow | 12 | 2 | 0 | Yes | No |
| 18896310 | STABLE LIQUID COMPOSITIONS OF GLUCAGON | September 2024 | November 2025 | Abandon | 13 | 2 | 0 | No | No |
| 18824445 | Formulations of MANP and Uses Thereof | September 2024 | August 2025 | Allow | 11 | 2 | 1 | Yes | No |
| 18674657 | POLYPEPTIDES HAVING ANTI-SENESCENT EFFECTS AND USES THEREOF | May 2024 | January 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18647078 | PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1 AGONIST, AN INSULIN AND METHIONINE | April 2024 | March 2026 | Abandon | 22 | 1 | 0 | No | No |
| 18626956 | CNP CYCLIC PEPTIDE, AND MEDICINE, EXTERNAL PREPARATION AND COSMETIC EACH CONTAINING SAID CYCLIC PEPTIDE | April 2024 | October 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18625923 | DESMOPRESSIN ORAL COMPOSITIONS | April 2024 | October 2024 | Allow | 38 | 1 | 1 | Yes | No |
| 18604400 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | March 2024 | November 2024 | Allow | 8 | 1 | 1 | No | No |
| 18598878 | GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOF | March 2024 | September 2025 | Abandon | 19 | 0 | 2 | No | No |
| 18402297 | PLANT MESSENGER PACKS ENCAPSULATING POLYPEPTIDES AND USES THEREOF | January 2024 | February 2026 | Abandon | 25 | 0 | 1 | No | No |
| 18386839 | SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | November 2023 | June 2025 | Allow | 19 | 1 | 1 | Yes | No |
| 18484819 | LIQUID DALBAVANCIN COMPOSITIONS | October 2023 | May 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18466693 | USE OF THYMOSIN ALPHA FOR THE TREATMENT OF SEPSIS | September 2023 | November 2025 | Abandon | 26 | 0 | 1 | No | No |
| 18365367 | LIPOPROTEIN COMPLEXES AND MANUFACTURING AND USES THEREOF | August 2023 | March 2024 | Allow | 7 | 1 | 0 | No | No |
| 18214651 | COMPOSITIONS AND METHODS OF CELL ATTACHMENT | June 2023 | April 2025 | Abandon | 22 | 1 | 1 | Yes | No |
| 18316893 | PEPTIDE MIMOTOPES OF CLAUDIN 18.2 AND USES THEREOF | May 2023 | December 2025 | Abandon | 31 | 1 | 1 | No | No |
| 18307124 | SOMATOSTATIN RECEPTOR AGONIST FORMULATIONS | April 2023 | March 2025 | Abandon | 23 | 1 | 1 | No | No |
| 18139030 | COMPOUNDS | April 2023 | June 2025 | Abandon | 26 | 2 | 1 | No | No |
| 18130299 | TREATMENT OF HMGB1-MEDIATED INFLAMMATION | April 2023 | September 2024 | Abandon | 17 | 1 | 1 | No | No |
| 18112262 | STABLE INTRANASAL FORMULATIONS OF CARBETOCIN | February 2023 | March 2026 | Abandon | 37 | 0 | 1 | No | No |
| 18170994 | COMPOSITIONS AND METHOD FOR OPTIMIZED PEPTIDE VACCINES USING RESIDUE OPTIMIZATION | February 2023 | April 2024 | Allow | 14 | 2 | 1 | Yes | No |
| 18145676 | Combination Therapy with Controlled-Release CNP Agonists | December 2022 | February 2026 | Allow | 38 | 4 | 1 | No | No |
| 18078518 | PROPYLENE GLYCOL-CONTAINING PEPTIDE FORMULATIONS WHICH ARE OPTIMAL FOR PRODUCTION AND FOR USE IN INJECTION DEVICES | December 2022 | June 2025 | Abandon | 31 | 1 | 1 | Yes | No |
| 17993916 | MULTIPARTICULATE GRANULATE COMPRISING INSULIN | November 2022 | July 2025 | Allow | 32 | 1 | 0 | No | No |
| 18054407 | USE OF BOTULINUM NEUROTOXIN IN THE TREATMENT OF SIALORRHEA | November 2022 | July 2025 | Allow | 33 | 4 | 0 | Yes | No |
| 17983349 | ACTIVATION OF (NA++K+)-ATPASE INHIBITS PLATELET AGGREGATION AND PREVENTS THROMBOSIS | November 2022 | December 2025 | Allow | 38 | 2 | 1 | Yes | No |
| 17919171 | STABLE READY TO DILUTE FORMULATIONS OF CARFILZOMIB | October 2022 | January 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17823018 | BCL-W Polypeptides and Mimetics for Treating or Preventing Chemotherapy-Induced Peripheral Neuropathy and Hearing Loss | August 2022 | June 2025 | Allow | 34 | 2 | 1 | Yes | No |
| 17800453 | SUBCUTANEOUS ADMINISTRATION OF FACTOR VIII | August 2022 | January 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17810574 | GLYCOTARGETING THERAPEUTICS | July 2022 | June 2025 | Abandon | 35 | 2 | 1 | No | No |
| 17810565 | GLYCOTARGETING THERAPEUTICS | July 2022 | May 2025 | Abandon | 35 | 2 | 1 | No | No |
| 17810561 | GLYCOTARGETING THERAPEUTICS | July 2022 | May 2025 | Abandon | 35 | 2 | 1 | No | No |
| 17810573 | GLYCOTARGETING THERAPEUTICS | July 2022 | June 2025 | Abandon | 35 | 2 | 1 | No | No |
| 17845144 | COMPOSITIONS AND METHODS FOR TARGETING NUCLEAR IMPORT SHUTTLES AND TREATING INFLAMMATORY DISORDERS | June 2022 | April 2024 | Allow | 22 | 1 | 1 | Yes | No |
| 17826659 | LIPOPROTEIN COMPLEXES AND MANUFACTURING AND USES THEREOF | May 2022 | March 2025 | Allow | 33 | 2 | 1 | Yes | No |
| 17729290 | COMPOSITIONS AND METHOD FOR OPTIMIZED PEPTIDE VACCINES USING RESIDUE OPTIMIZATION | April 2022 | January 2023 | Allow | 8 | 2 | 1 | Yes | No |
| 17727677 | METALLOENZYMES FOR BIOMOLECULAR RECOGNITION OF N-TERMINAL MODIFIED PEPTIDES | April 2022 | November 2025 | Abandon | 43 | 4 | 2 | Yes | No |
| 17768514 | MRNAS ENCODING GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR FOR TREATING PARKINSON'S DISEASE | April 2022 | September 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17718906 | RECOMBINANT GLYCOSYLATED ECULIZUMAB AND ECULIZUMAB VARIANTS | April 2022 | November 2024 | Abandon | 32 | 1 | 1 | No | No |
| 17696769 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW NPR-C BINDING | March 2022 | January 2026 | Allow | 46 | 3 | 1 | Yes | No |
| 17650975 | RECOMBINANT VECTOR FOR EXPRESSING TARGET PROTEIN IN PLANT CELL | February 2022 | October 2023 | Allow | 20 | 0 | 1 | Yes | No |
| 17589588 | ANTIBIOTIC CANNABINOID-TERPENE FORMULATIONS | January 2022 | June 2023 | Allow | 17 | 2 | 1 | Yes | No |
| 17626463 | EXCIPIENT FOR BIOTHERAPEUTICS | January 2022 | October 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17566249 | PEPTIDE AND METHOD FOR MANUFACTURING SAME | December 2021 | January 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17555374 | USE OF PROTEIN-BASED LONG-ACTING PREPARATION IN IMPROVING SEXUAL DYSFUNCTION | December 2021 | December 2025 | Abandon | 48 | 2 | 1 | Yes | No |
| 17550098 | Cystatin C and Cystatin 9 to Treat Inflammation Caused by Bacteria | December 2021 | May 2025 | Abandon | 41 | 2 | 1 | Yes | No |
| 17619168 | PEPTIDES AND METHODS OF USE THEREOF IN TREATING UVEITIS | December 2021 | July 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17643533 | CYCLIC PEPTIDE, CELL SCAFFOLD MATERIAL, CELL SEPARATING MATERIAL, AND MEDIUM | December 2021 | March 2026 | Allow | 51 | 2 | 1 | Yes | No |
| 17616877 | PEPTIDE INHIBITORS FOR THE INHIBITION OF HIV CAPSID | December 2021 | December 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17527408 | WHEY PROTEIN MICELLES AGAINST MUSCLE ATROPHY AND SARCOPENIA | November 2021 | March 2025 | Abandon | 40 | 3 | 0 | Yes | No |
| 17607247 | ANTIBIOTIC CANNABINOID-TERPENE FORMULATIONS | October 2021 | October 2024 | Abandon | 36 | 0 | 1 | No | No |
| 17605859 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION | October 2021 | January 2026 | Allow | 51 | 1 | 2 | No | No |
| 17604925 | SHORT SYNTHETIC PEPTIDES AND THEIR USES FOR TREATING RETINAL DEGENERATIVE DISEASES AND/OR TISSUE INJURIES | October 2021 | September 2024 | Allow | 35 | 1 | 1 | Yes | No |
| 17501486 | ALPHA-V BETA-6 INTEGRIN LIGANDS AND USES THEREOF | October 2021 | May 2024 | Abandon | 31 | 1 | 1 | Yes | No |
| 17401929 | PHARMACEUTICAL COMPOSITIONS | August 2021 | March 2025 | Allow | 43 | 2 | 1 | No | No |
| 17396947 | ARTIFICIAL SYNAPSES | August 2021 | November 2024 | Abandon | 40 | 5 | 1 | Yes | No |
| 17427751 | Peptide Ligands of the Gdnf Family Receptor A-Like (Gfral) Receptor | August 2021 | September 2025 | Allow | 49 | 2 | 1 | Yes | No |
| 17383617 | PLANT MESSENGER PACKS ENCAPSULATING POLYPEPTIDES AND USES THEREOF | July 2021 | February 2024 | Abandon | 31 | 4 | 0 | Yes | No |
| 17421672 | PROCESS FOR SOLID-PHASE PEPTIDE SYNTHESIS AND DEVICE | July 2021 | December 2025 | Allow | 54 | 1 | 1 | Yes | No |
| 17366332 | PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1 AGONIST, AN INSULIN AND METHIONINE | July 2021 | July 2024 | Abandon | 36 | 2 | 0 | No | No |
| 17352506 | INJECTABLE COMPOSITION FOR PREVENTING HAIR LOSS OR STIMULATING HAIR GROWTH | June 2021 | July 2024 | Allow | 37 | 2 | 1 | Yes | No |
| 17350363 | CONTROLLED RELEASE PEPTIDE FORMULATIONS | June 2021 | October 2024 | Abandon | 40 | 2 | 1 | No | No |
| 17348023 | METHOD AND FORMULATION FOR INHALATION | June 2021 | August 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 17298512 | Modified GIP Peptide Analogues | May 2021 | March 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17306435 | ENGINEERED PD-1 VARIANTS | May 2021 | October 2023 | Allow | 29 | 1 | 1 | Yes | No |
| 17243096 | COMPOSITIONS AND METHOD FOR OPTIMIZED PEPTIDE VACCINES USING RESIDUE OPTIMIZATION | April 2021 | December 2021 | Allow | 8 | 3 | 1 | Yes | No |
| 17202064 | IDENTIFICATION OF CHANNELRHODOPSIN-2 (CHR2) MUTATIONS AND METHODS OF USE | March 2021 | May 2024 | Abandon | 38 | 2 | 1 | No | No |
| 17197980 | MULTIFUNCTIONAL OPIOID RECEPTOR LIGANDS AND METHODS OF TREATING PAIN | March 2021 | April 2025 | Abandon | 49 | 2 | 1 | No | No |
| 17165070 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING POLYCYSTIC OVARY SYNDROME | February 2021 | January 2023 | Abandon | 23 | 1 | 1 | No | No |
| 17264793 | ENGINEERED HEMICHANNELS, ENGINEERED VESICLES, AND USES THEREOF | January 2021 | February 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17141778 | PEPTIDES FOR USE IN PROMOTING TRANSPORT OF GLUCOSE | January 2021 | April 2025 | Allow | 52 | 2 | 1 | Yes | Yes |
| 17142026 | TREATING INFLAMMATION USING LLP2A-BISPHOSPHONATE CONJUGATES AND MESENCHYMAL STEM CELLS | January 2021 | November 2025 | Allow | 59 | 4 | 1 | No | No |
| 17138448 | PEPTIDIC TGF-BETA ANTAGONISTS | December 2020 | June 2023 | Allow | 29 | 1 | 1 | Yes | No |
| 17253333 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | December 2020 | May 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17113957 | METHODS FOR DIAGNOSING AND ASSESSING RISK OF DEVELOPING GLOMERULOSCLEROSIS | December 2020 | June 2024 | Allow | 42 | 2 | 1 | Yes | No |
| 15734957 | METHODS OF USE OF CD24 FOR THE PREVENTION AND TREATMENT OF LEUKEMIA RELAPSE | December 2020 | October 2023 | Allow | 34 | 1 | 1 | Yes | No |
| 17086786 | Q-PEPTIDE HYDROGEL PROMOTES IMMUNE MODULATION AND MACROPHAGE DIFFERENTIATION | November 2020 | May 2023 | Allow | 31 | 1 | 1 | Yes | No |
| 17075295 | LONG-ACTING FATTY ACID-CONJUGATED GnRH DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | October 2020 | March 2022 | Abandon | 17 | 2 | 1 | Yes | No |
| 17032540 | PREPARATION AND APPLICATION OF SURFACE DOUBLE MODIFIED HUMAN SERUM ALBUMIN AS TARGETING NANO DRUG CARRIER | September 2020 | June 2024 | Abandon | 45 | 2 | 1 | No | No |
| 17041638 | ANTIMICROBIAL, BACTERIOPHAGE-DERIVED POLYPEPTIDES AND THEIR USE AGAINST GRAM-NEGATIVE BACTERIA | September 2020 | July 2024 | Abandon | 46 | 1 | 1 | No | No |
| 17041459 | Targeted Thrombolysis for Treatment of Microvascular Thrombosis | September 2020 | September 2024 | Abandon | 48 | 1 | 1 | Yes | No |
| 17016473 | TREATMENT OF HMGB1-MEDIATED INFLAMMATION | September 2020 | December 2022 | Allow | 27 | 1 | 1 | Yes | No |
| 16997760 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | August 2020 | September 2022 | Abandon | 25 | 0 | 1 | No | No |
| 16987764 | MODULATION OF STRUCTURED POLYPEPTIDE SPECIFICITY | August 2020 | April 2023 | Allow | 32 | 2 | 1 | Yes | No |
| 16943822 | MULTIPARTICULATE GRANULATE COMPRISING INSULIN | July 2020 | December 2022 | Abandon | 28 | 1 | 0 | No | No |
| 16943114 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | July 2020 | February 2025 | Allow | 55 | 4 | 1 | Yes | No |
| 16965814 | AFFINITY LIGANDS FOR ANTIBODY FC REGION | July 2020 | October 2024 | Allow | 50 | 4 | 1 | No | No |
| 16937316 | COMPOUNDS USEFUL TO TREAT METABOLIC DISORDERS | July 2020 | April 2025 | Abandon | 57 | 4 | 1 | No | No |
| 16936177 | POLYPEPTIDES HAVING ANTI-SENESCENT EFFECTS AND USES THEREOF | July 2020 | January 2025 | Allow | 54 | 6 | 1 | Yes | No |
| 16911712 | GALACTOENGINEERED IMMUNOGLOBULIN 1 ANTIBODIES | June 2020 | August 2022 | Abandon | 26 | 0 | 1 | No | No |
| 16910945 | PROPYLENE GLYCOL-CONTAINING PEPTIDE FORMULATIONS WHICH ARE OPTIMAL FOR PRODUCTION AND FOR USE IN INJECTION DEVICES | June 2020 | December 2022 | Abandon | 30 | 3 | 1 | Yes | Yes |
| 16955896 | POLYMYXIN-BASED PHARMACEUTICAL COMPOSITION FOR TREATING INFECTIOUS DISEASES | June 2020 | August 2021 | Allow | 14 | 2 | 1 | No | No |
| 16903107 | CYSTATIN C AND CYSTATIN 9 TO TREAT GUT INFLAMMATION CAUSED BY THERMAL INJURY | June 2020 | April 2024 | Allow | 46 | 3 | 1 | Yes | No |
| 16899192 | MODULATION OF STRUCTURED POLYPEPTIDE SPECIFICITY | June 2020 | October 2023 | Allow | 40 | 3 | 1 | Yes | No |
| 16768584 | PEPTIDE HORMONE WITH ONE OR MORE O-GLYCANS | May 2020 | May 2023 | Abandon | 35 | 1 | 1 | Yes | No |
| 16881314 | USE OF THYMOSIN ALPHA FOR THE TREATMENT OF SEPSIS | May 2020 | November 2022 | Abandon | 30 | 1 | 1 | Yes | No |
| 16876683 | NOVEL MODULATORS OF MELANOCORTIN RECEPTORS FOR THE TREATMENT OF DEPRESSION AND ANXIETY | May 2020 | September 2022 | Allow | 28 | 2 | 1 | Yes | No |
| 16763963 | USE OF CELL MEMBRANE-BOUND SIGNALING FACTORS | May 2020 | November 2024 | Abandon | 54 | 3 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner D' AMBROSIO, THEA.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner D' AMBROSIO, THEA works in Art Unit 1654 and has examined 305 patent applications in our dataset. With an allowance rate of 56.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.
Examiner D' AMBROSIO, THEA's allowance rate of 56.7% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by D' AMBROSIO, THEA receive 2.73 office actions before reaching final disposition. This places the examiner in the 80% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by D' AMBROSIO, THEA is 38 months. This places the examiner in the 29% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +63.0% benefit to allowance rate for applications examined by D' AMBROSIO, THEA. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 20.4% of applications are subsequently allowed. This success rate is in the 22% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 23.0% of cases where such amendments are filed. This entry rate is in the 30% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 80.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 62% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 71.4% of appeals filed. This is in the 58% percentile among all examiners. Of these withdrawals, 90.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 84.3% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.2% of allowed cases (in the 62% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.